History- Diagnosis in February, metastasis to thyroid, lymph nodes, chest wall. Malignant pleural effusion-had pleurex cathether which was recently removed due to little fluid. Pdl1 40%, KRAS mutation
Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.
Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.
Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.
One of the more eagerly awaited clinical trials in lung cancer this year is the PointBreak study that tried to identify whether an Alimta (pemetrexed)-based first line and maintenance chemo strategy is significantly superior to a well-established standard first line and maintenance therapy regimen. Specifically, this trial randomized 939 chemo-naive patients wi